Ernexa Therapeutics vs Exicure
ERNA and XCUR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ERNA and XCUR compare
Exicure is the larger company, worth 2.6 times as much as Ernexa Therapeutics ($7.1M against $2.7M).
Ernexa Therapeutics scores higher on the StockData Score (6 against 4 for Exicure), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ERNA | XCUR |
|---|---|---|
| Size and price | ||
| Market cap | $2.7M | $7.1M |
| Share price | $1.68 | $1.08 |
| Change, 1 year | −95.8% | −70.0% |
| Change, 5 years | −100.0% | −98.4% |
| Beta (5Y) | 1.56 | 1.25 |
| Employees | 5 | 8 |
| StockData Score | ||
| Total score | 6 (better) | 4 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 5 (better) | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 0.6× (better) | 7.2× |
| FCF yield | −392% | – |
| Profitability | ||
| Return on equity | −352% | −168% (better) |
| Return on invested capital | – | −4377% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 2.57 (better) | 0.56 |
| Altman Z-score | −56.44 | −27.36 (better) |
| Piotroski F-score | 3 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | – | 0.00% |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | – | 2.1% |
| Held by insiders | – | 92.6% |
| Insider net buying, 12 months | $2.0M (better) | −$11.6M |
| Short interest, % of float | – | 10.8% |
Go deeper
- ERNA stock overview
- ERNA income statement
- ERNA valuation and score
- XCUR stock overview
- XCUR income statement
- XCUR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.